Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

20.02 +1.90 (+10.49%)
Streaming Delayed Price Updated: 10:35 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will... 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Legend Biotech's Earnings ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Legend Biotech? ↗
 
Via Benzinga
Legend Biotech Considering Second Listing Outside US: Report ↗
Via Stocktwits
News headline image
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline. 
Via The Motley Fool
News headline image
How Do Investors Really Feel About Legend Biotech? ↗
 
Via Benzinga
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia ↗
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter ↗
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter 
Via The Motley Fool
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
AMD To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
News headline image
Expert Outlook: Legend Biotech Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Legend Biotech In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
News headline image
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales ↗
Legend Biotech's Q2 2025 earnings show revenue beat at $255.1M, driven by strong CARVYKTI sales, but EPS missed at -$0.34. Stock rose 1.4% pre-market. 
Via Chartmill
News headline image
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.